

1 ENGROSSED SENATE
2 BILL NO. 1783

By: Paxton of the Senate

3 and

4 Kerbs of the House

5
6 An Act relating to the Uniform Controlled Dangerous
7 Substances Act; amending 63 O.S. 2011, Section 2-101,
8 as last amended by Section 16, Chapter 428, O.S.L.
9 2019 (63 O.S. Supp. 2019, Section 2-101), which
10 relates to definitions; modifying definition; and
11 providing an effective date.

12 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

13 SECTION 1. AMENDATORY 63 O.S. 2011, Section 2-101, as
14 last amended by Section 16, Chapter 428, O.S.L. 2019 (63 O.S. Supp.
15 2019, Section 2-101), is amended to read as follows:

16 Section 2-101. As used in the Uniform Controlled Dangerous
17 Substances Act:

18 1. "Administer" means the direct application of a controlled
19 dangerous substance, whether by injection, inhalation, ingestion or
20 any other means, to the body of a patient, animal or research
21 subject by:

22 a. a practitioner (or, in the presence of the
23 practitioner, by the authorized agent of the
24 practitioner), or

b. the patient or research subject at the direction and
in the presence of the practitioner;

2. "Agent" means a peace officer appointed by and who acts on
behalf of the Director of the Oklahoma State Bureau of Narcotics and
Dangerous Drugs Control or an authorized person who acts on behalf
of or at the direction of a person who manufactures, distributes,
dispenses, prescribes, administers or uses for scientific purposes
controlled dangerous substances but does not include a common or
contract carrier, public warehouser or employee thereof, or a person
required to register under the Uniform Controlled Dangerous
Substances Act;

3. "Board" means the Advisory Board to the Director of the
Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;

4. "Bureau" means the Oklahoma State Bureau of Narcotics and
Dangerous Drugs Control;

5. "Coca leaves" includes cocaine and any compound,
manufacture, salt, derivative, mixture or preparation of coca
leaves, except derivatives of coca leaves which do not contain
cocaine or ecgonine;

6. "Commissioner" or "Director" means the Director of the
Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;

7. "Control" means to add, remove or change the placement of a
drug, substance or immediate precursor under the Uniform Controlled
Dangerous Substances Act;

1 8. "Controlled dangerous substance" means a drug, substance or
2 immediate precursor in Schedules I through V of the Uniform
3 Controlled Dangerous Substances Act or any drug, substance or
4 immediate precursor listed either temporarily or permanently as a
5 federally controlled substance. Any conflict between state and
6 federal law with regard to the particular schedule in which a
7 substance is listed shall be resolved in favor of state law;

8 9. "Counterfeit substance" means a controlled substance which,
9 or the container or labeling of which without authorization, bears
10 the trademark, trade name or other identifying marks, imprint,
11 number or device or any likeness thereof of a manufacturer,
12 distributor or dispenser other than the person who in fact
13 manufactured, distributed or dispensed the substance;

14 10. "Deliver" or "delivery" means the actual, constructive or
15 attempted transfer from one person to another of a controlled
16 dangerous substance or drug paraphernalia, whether or not there is
17 an agency relationship;

18 11. "Dispense" means to deliver a controlled dangerous
19 substance to an ultimate user or human research subject by or
20 pursuant to the lawful order of a practitioner, including the
21 prescribing, administering, packaging, labeling or compounding
22 necessary to prepare the substance for such distribution.

23 "Dispenser" is a practitioner who delivers a controlled dangerous
24 substance to an ultimate user or human research subject;

1 12. "Distribute" means to deliver other than by administering
2 or dispensing a controlled dangerous substance;

3 13. "Distributor" means a commercial entity engaged in the
4 distribution or reverse distribution of narcotics and dangerous
5 drugs and who complies with all regulations promulgated by the
6 federal Drug Enforcement Administration and the Oklahoma State
7 Bureau of Narcotics and Dangerous Drugs Control;

8 14. "Drug" means articles:

9 a. recognized in the official United States

10 Pharmacopoeia, official Homeopathic Pharmacopoeia of
11 the United States, or official National Formulary, or
12 any supplement to any of them,

13 b. intended for use in the diagnosis, cure, mitigation,
14 treatment or prevention of disease in man or other
15 animals,

16 c. other than food, intended to affect the structure or
17 any function of the body of man or other animals, and

18 d. intended for use as a component of any article
19 specified in this paragraph;

20 provided, however, the term "drug" does not include devices or their
21 components, parts or accessories;

22 15. "Drug-dependent person" means a person who is using a
23 controlled dangerous substance and who is in a state of psychic or
24 physical dependence, or both, arising from administration of that

1 controlled dangerous substance on a continuous basis. Drug
2 dependence is characterized by behavioral and other responses which
3 include a strong compulsion to take the substance on a continuous
4 basis in order to experience its psychic effects, or to avoid the
5 discomfort of its absence;

6 16. "Home care agency" means any sole proprietorship,
7 partnership, association, corporation, or other organization which
8 administers, offers, or provides home care services, for a fee or
9 pursuant to a contract for such services, to clients in their place
10 of residence;

11 17. "Home care services" means skilled or personal care
12 services provided to clients in their place of residence for a fee;

13 18. "Hospice" means a centrally administered, nonprofit or
14 profit, medically directed, nurse-coordinated program which provides
15 a continuum of home and inpatient care for the terminally ill
16 patient and the patient's family. Such term shall also include a
17 centrally administered, nonprofit or profit, medically directed,
18 nurse-coordinated program if such program is licensed pursuant to
19 the provisions of the Uniform Controlled Dangerous Substances Act.
20 A hospice program offers palliative and supportive care to meet the
21 special needs arising out of the physical, emotional and spiritual
22 stresses which are experienced during the final stages of illness
23 and during dying and bereavement. This care is available twenty-
24 four (24) hours a day, seven (7) days a week, and is provided on the

1 basis of need, regardless of ability to pay. "Class A" Hospice
2 refers to Medicare certified hospices. "Class B" refers to all
3 other providers of hospice services;

4 19. "Imitation controlled substance" means a substance that is
5 not a controlled dangerous substance, which by dosage unit
6 appearance, color, shape, size, markings or by representations made,
7 would lead a reasonable person to believe that the substance is a
8 controlled dangerous substance. In the event the appearance of the
9 dosage unit is not reasonably sufficient to establish that the
10 substance is an "imitation controlled substance", the court or
11 authority concerned should consider, in addition to all other
12 factors, the following factors as related to "representations made"
13 in determining whether the substance is an "imitation controlled
14 substance":

- 15 a. statements made by an owner or by any other person in
16 control of the substance concerning the nature of the
17 substance, or its use or effect,
- 18 b. statements made to the recipient that the substance
19 may be resold for inordinate profit,
- 20 c. whether the substance is packaged in a manner normally
21 used for illicit controlled substances,
- 22 d. evasive tactics or actions utilized by the owner or
23 person in control of the substance to avoid detection
24 by law enforcement authorities,

- 1 e. prior convictions, if any, of an owner, or any other
2 person in control of the object, under state or
3 federal law related to controlled substances or fraud,
4 and
5 f. the proximity of the substances to controlled
6 dangerous substances;

7 20. "Immediate precursor" means a substance which the Director
8 has found to be and by regulation designates as being the principal
9 compound commonly used or produced primarily for use, and which is
10 an immediate chemical intermediary used, or likely to be used, in
11 the manufacture of a controlled dangerous substance, the control of
12 which is necessary to prevent, curtail or limit such manufacture;

13 21. "Laboratory" means a laboratory approved by the Director as
14 proper to be entrusted with the custody of controlled dangerous
15 substances and the use of controlled dangerous substances for
16 scientific and medical purposes and for purposes of instruction;

17 22. "Manufacture" means the production, preparation,
18 propagation, compounding or processing of a controlled dangerous
19 substance, either directly or indirectly by extraction from
20 substances of natural or synthetic origin, or independently by means
21 of chemical synthesis or by a combination of extraction and chemical
22 synthesis. "Manufacturer" includes any person who packages,
23 repackages or labels any container of any controlled dangerous
24

1 substance, except practitioners who dispense or compound
2 prescription orders for delivery to the ultimate consumer;

3 23. "Marijuana" means all parts of the plant *Cannabis sativa*
4 L., whether growing or not; the seeds thereof; the resin extracted
5 from any part of such plant; and every compound, manufacture, salt,
6 derivative, mixture or preparation of such plant, its seeds or
7 resin, but shall not include:

- 8 a. the mature stalks of such plant or fiber produced from
9 such stalks,
- 10 b. oil or cake made from the seeds of such plant,
11 including cannabidiol derived from the seeds of the
12 marijuana plant,
- 13 c. any other compound, manufacture, salt, derivative,
14 mixture or preparation of such mature stalks (except
15 the resin extracted therefrom), including cannabidiol
16 derived from mature stalks, fiber, oil or cake,
- 17 d. the sterilized seed of such plant which is incapable
18 of germination,
- 19 e. for any person participating in a clinical trial to
20 administer cannabidiol for the treatment of severe
21 forms of epilepsy pursuant to Section 2-802 of this
22 title, a drug or substance approved by the federal
23 Food and Drug Administration for use by those
24 participants,

- 1 f. for any person or the parents, legal guardians or
2 caretakers of the person who have received a written
3 certification from a physician licensed in this state
4 that the person has been diagnosed by a physician as
5 having Lennox-Gastaut Syndrome, Dravet Syndrome, also
6 known as Severe Myoclonic Epilepsy of Infancy, or any
7 other severe form of epilepsy that is not adequately
8 treated by traditional medical therapies, spasticity
9 due to multiple sclerosis or due to paraplegia,
10 intractable nausea and vomiting, appetite stimulation
11 with chronic wasting diseases, the substance
12 cannabidiol, a nonpsychoactive cannabinoid, found in
13 the plant Cannabis sativa L. or any other preparation
14 thereof, that has a tetrahydrocannabinol concentration
15 of not more than three-tenths of one percent (0.3%)
16 and that is delivered to the patient in the form of a
17 liquid,
- 18 g. any federal Food and Drug Administration-approved
19 cannabidiol drug or substance, or
- 20 h. industrial hemp, from the plant Cannabis sativa L. and
21 any part of such plant, whether growing or not, with a
22 delta-9 tetrahydrocannabinol concentration of not more
23 than three-tenths of one percent (0.3%) on a dry
24 weight basis which shall ~~not be grown anywhere in the~~

~~State of Oklahoma but may be shipped to Oklahoma~~
~~pursuant to the provisions of subparagraph e or f of~~
~~this paragraph~~ only be grown pursuant to the Oklahoma
Industrial Hemp Program and may be shipped intrastate
and interstate;

24. "Medical purpose" means an intention to utilize a controlled dangerous substance for physical or mental treatment, for diagnosis, or for the prevention of a disease condition not in violation of any state or federal law and not for the purpose of satisfying physiological or psychological dependence or other abuse;

25. "Mid-level practitioner" means an Advanced Practice Registered Nurse as defined and within parameters specified in Section 567.3a of Title 59 of the Oklahoma Statutes, or a certified animal euthanasia technician as defined in Section 698.2 of Title 59 of the Oklahoma Statutes, or an animal control officer registered by the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control under subsection B of Section 2-301 of this title within the parameters of such officer's duty under Sections 501 through 508 of Title 4 of the Oklahoma Statutes;

26. "Narcotic drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:

a. opium, coca leaves and opiates,

- 1 b. a compound, manufacture, salt, derivative or
2 preparation of opium, coca leaves or opiates,
3 c. cocaine, its salts, optical and geometric isomers, and
4 salts of isomers,
5 d. ecgonine, its derivatives, their salts, isomers and
6 salts of isomers, and
7 e. a substance, and any compound, manufacture, salt,
8 derivative or preparation thereof, which is chemically
9 identical with any of the substances referred to in
10 subparagraphs a through d of this paragraph, except
11 that the words "narcotic drug" as used in Section 2-
12 101 et seq. of this title shall not include
13 decocainized coca leaves or extracts of coca leaves,
14 which extracts do not contain cocaine or ecgonine;

15 27. "Opiate" or "opioid" means any Schedule II, III, IV or V
16 substance having an addiction-forming or addiction-sustaining
17 liability similar to morphine or being capable of conversion into a
18 drug having such addiction-forming or addiction-sustaining
19 liability. The terms do not include, unless specifically designated
20 as controlled under the Uniform Controlled Dangerous Substances Act,
21 the dextrorotatory isomer of 3-methoxy-n-methyl-morphinan and its
22 salts (dextromethorphan). The terms do include the racemic and
23 levorotatory forms;
24

1 28. "Opium poppy" means the plant of the species *Papaver*
2 *somniferum* L., except the seeds thereof;

3 29. "Peace officer" means a police officer, sheriff, deputy
4 sheriff, district attorney's investigator, investigator from the
5 Office of the Attorney General, or any other person elected or
6 appointed by law to enforce any of the criminal laws of this state
7 or of the United States;

8 30. "Person" means an individual, corporation, government or
9 governmental subdivision or agency, business trust, estate, trust,
10 partnership or association, or any other legal entity;

11 31. "Poppy straw" means all parts, except the seeds, of the
12 opium poppy, after mowing;

13 32. "Practitioner" means:

- 14 a. (1) a medical doctor or osteopathic physician,
15 (2) a dentist,
16 (3) a podiatrist,
17 (4) an optometrist,
18 (5) a veterinarian,
19 (6) a physician assistant or Advanced Practice
20 Registered Nurse under the supervision of a
21 licensed medical doctor or osteopathic physician,
22 (7) a scientific investigator, or
23 (8) any other person,
24

1 licensed, registered or otherwise permitted to
2 prescribe, distribute, dispense, conduct research with
3 respect to, use for scientific purposes or administer
4 a controlled dangerous substance in the course of
5 professional practice or research in this state, or
6 b. a pharmacy, hospital, laboratory or other institution
7 licensed, registered or otherwise permitted to
8 distribute, dispense, conduct research with respect
9 to, use for scientific purposes or administer a
10 controlled dangerous substance in the course of
11 professional practice or research in this state;

12 33. "Production" includes the manufacture, planting,
13 cultivation, growing or harvesting of a controlled dangerous
14 substance;

15 34. "State" means the State of Oklahoma or any other state of
16 the United States;

17 35. "Ultimate user" means a person who lawfully possesses a
18 controlled dangerous substance for the person's own use or for the
19 use of a member of the person's household or for administration to
20 an animal owned by the person or by a member of the person's
21 household;

22 36. "Drug paraphernalia" means all equipment, products and
23 materials of any kind which are used, intended for use, or fashioned
24 specifically for use in planting, propagating, cultivating, growing,

1 harvesting, manufacturing, compounding, converting, producing,
2 processing, preparing, testing, analyzing, packaging, repackaging,
3 storing, containing, concealing, injecting, ingesting, inhaling or
4 otherwise introducing into the human body, a controlled dangerous
5 substance in violation of the Uniform Controlled Dangerous
6 Substances Act including, but not limited to:

- 7 a. kits used, intended for use, or fashioned specifically
8 for use in planting, propagating, cultivating, growing
9 or harvesting of any species of plant which is a
10 controlled dangerous substance or from which a
11 controlled dangerous substance can be derived,
- 12 b. kits used, intended for use, or fashioned specifically
13 for use in manufacturing, compounding, converting,
14 producing, processing or preparing controlled
15 dangerous substances,
- 16 c. isomerization devices used, intended for use, or
17 fashioned specifically for use in increasing the
18 potency of any species of plant which is a controlled
19 dangerous substance,
- 20 d. testing equipment used, intended for use, or fashioned
21 specifically for use in identifying, or in analyzing
22 the strength, effectiveness or purity of controlled
23 dangerous substances,

- e. scales and balances used, intended for use, or fashioned specifically for use in weighing or measuring controlled dangerous substances,
- f. diluents and adulterants, such as quinine hydrochloride, mannitol, mannite, dextrose and lactose, used, intended for use, or fashioned specifically for use in cutting controlled dangerous substances,
- g. separation gins and sifters used, intended for use, or fashioned specifically for use in removing twigs and seeds from, or in otherwise cleaning or refining, marijuana,
- h. blenders, bowls, containers, spoons and mixing devices used, intended for use, or fashioned specifically for use in compounding controlled dangerous substances,
- i. capsules, balloons, envelopes and other containers used, intended for use, or fashioned specifically for use in packaging small quantities of controlled dangerous substances,
- j. containers and other objects used, intended for use, or fashioned specifically for use in parenterally injecting controlled dangerous substances into the human body,

- 1 k. hypodermic syringes, needles and other objects used,
2 intended for use, or fashioned specifically for use in
3 parenterally injecting controlled dangerous substances
4 into the human body,
- 5 1. objects used, intended for use, or fashioned
6 specifically for use in ingesting, inhaling or
7 otherwise introducing marijuana, cocaine, hashish or
8 hashish oil into the human body, such as:
- 9 (1) metal, wooden, acrylic, glass, stone, plastic or
10 ceramic pipes with or without screens, permanent
11 screens, hashish heads or punctured metal bowls,
12 (2) water pipes,
13 (3) carburetion tubes and devices,
14 (4) smoking and carburetion masks,
15 (5) roach clips, meaning objects used to hold burning
16 material, such as a marijuana cigarette, that has
17 become too small or too short to be held in the
18 hand,
19 (6) miniature cocaine spoons and cocaine vials,
20 (7) chamber pipes,
21 (8) carburetor pipes,
22 (9) electric pipes,
23 (10) air-driven pipes,
24 (11) chillums,

- 1 (12) bongs, or
2 (13) ice pipes or chillers,
3 m. all hidden or novelty pipes, and
4 n. any pipe that has a tobacco bowl or chamber of less
5 than one-half (1/2) inch in diameter in which there is
6 any detectable residue of any controlled dangerous
7 substance as defined in this section or any other
8 substances not legal for possession or use;

9 provided, however, the term "drug paraphernalia" shall not include
10 separation gins intended for use in preparing tea or spice, clamps
11 used for constructing electrical equipment, water pipes designed for
12 ornamentation in which no detectable amount of an illegal substance
13 is found or pipes designed and used solely for smoking tobacco,
14 traditional pipes of an American Indian tribal religious ceremony,
15 or antique pipes that are thirty (30) years of age or older;

16 37. a. "Synthetic controlled substance" means a substance:

- 17 (1) the chemical structure of which is substantially
18 similar to the chemical structure of a controlled
19 dangerous substance in Schedule I or II,
20 (2) which has a stimulant, depressant, or
21 hallucinogenic effect on the central nervous
22 system that is substantially similar to or
23 greater than the stimulant, depressant or
24 hallucinogenic effect on the central nervous

1 system of a controlled dangerous substance in
2 Schedule I or II, or

3 (3) with respect to a particular person, which such
4 person represents or intends to have a stimulant,
5 depressant, or hallucinogenic effect on the
6 central nervous system that is substantially
7 similar to or greater than the stimulant,
8 depressant, or hallucinogenic effect on the
9 central nervous system of a controlled dangerous
10 substance in Schedule I or II.

11 b. The designation of gamma butyrolactone or any other
12 chemical as a precursor, pursuant to Section 2-322 of
13 this title, does not preclude a finding pursuant to
14 subparagraph a of this paragraph that the chemical is
15 a synthetic controlled substance.

16 c. "Synthetic controlled substance" does not include:

17 (1) a controlled dangerous substance,
18 (2) any substance for which there is an approved new
19 drug application,
20 (3) with respect to a particular person any
21 substance, if an exemption is in effect for
22 investigational use, for that person under the
23 provisions of Section 505 of the Federal Food,
24 Drug and Cosmetic Act, Title 21 of the United

1 States Code, Section 355, to the extent conduct
2 with respect to such substance is pursuant to
3 such exemption, or

4 (4) any substance to the extent not intended for
5 human consumption before such an exemption takes
6 effect with respect to that substance.

7 d. Prima facie evidence that a substance containing
8 salvia divinorum has been enhanced, concentrated or
9 chemically or physically altered shall give rise to a
10 rebuttable presumption that the substance is a
11 synthetic controlled substance;

12 38. "Tetrahydrocannabinols" means all substances that have been
13 chemically synthesized to emulate the tetrahydrocannabinols of
14 marijuana;

15 39. "Isomer" means the optical isomer, except as used in
16 subsections C and F of Section 2-204 of this title and paragraph 4
17 of subsection A of Section 2-206 of this title. As used in
18 subsections C and F of Section 2-204 of this title, "isomer" means
19 the optical, positional or geometric isomer. As used in paragraph 4
20 of subsection A of Section 2-206 of this title, the term "isomer"
21 means the optical or geometric isomer;

22 40. "Hazardous materials" means materials, whether solid,
23 liquid or gas, which are toxic to human, animal, aquatic or plant
24

1 life, and the disposal of which materials is controlled by state or
2 federal guidelines;

3 41. "Anhydrous ammonia" means any substance that exhibits
4 cryogenic evaporative behavior and tests positive for ammonia;

5 42. "Acute pain" means pain, whether resulting from disease,
6 accidental or intentional trauma or other cause, that the
7 practitioner reasonably expects to last only a short period of time.
8 "Acute pain" does not include chronic pain, pain being treated as
9 part of cancer care, hospice or other end-of-life care, or pain
10 being treated as part of palliative care;

11 43. "Chronic pain" means pain that persists beyond the usual
12 course of an acute disease or healing of an injury. "Chronic pain"
13 may or may not be associated with an acute or chronic pathologic
14 process that causes continuous or intermittent pain over months or
15 years;

16 44. "Initial prescription" means a prescription issued to a
17 patient who:

- 18 a. has never previously been issued a prescription for
19 the drug or its pharmaceutical equivalent in the past
20 year, or
21 b. requires a prescription for the drug or its
22 pharmaceutical equivalent due to a surgical procedure
23 or new acute event and has previously had a
24

1 prescription for the drug or its pharmaceutical
2 equivalent within the past year.

3 When determining whether a patient was previously issued a
4 prescription for a drug or its pharmaceutical equivalent, the
5 practitioner shall consult with the patient and review the medical
6 record and prescription monitoring information of the patient;

7 45. "Patient-provider agreement" means a written contract or
8 agreement that is executed between a practitioner and a patient,
9 prior to the commencement of treatment for chronic pain using an
10 opioid drug as a means to:

- 11 a. explain the possible risk of development of physical
12 or psychological dependence in the patient and prevent
13 the possible development of addiction,
- 14 b. document the understanding of both the practitioner
15 and the patient regarding the patient-provider
16 agreement of the patient,
- 17 c. establish the rights of the patient in association
18 with treatment and the obligations of the patient in
19 relation to the responsible use, discontinuation of
20 use, and storage of opioid drugs, including any
21 restrictions on the refill of prescriptions or the
22 acceptance of opioid prescriptions from practitioners,
- 23 d. identify the specific medications and other modes of
24 treatment, including physical therapy or exercise,

- 1 relaxation or psychological counseling, that are
2 included as a part of the patient-provider agreement,
3 e. specify the measures the practitioner may employ to
4 monitor the compliance of the patient including, but
5 not limited to, random specimen screens and pill
6 counts, and
7 f. delineate the process for terminating the agreement,
8 including the consequences if the practitioner has
9 reason to believe that the patient is not complying
10 with the terms of the agreement. Compliance with the
11 "consent items" shall constitute a valid, informed
12 consent for opioid therapy. The practitioner shall be
13 held harmless from civil litigation for failure to
14 treat pain if the event occurs because of nonadherence
15 by the patient with any of the provisions of the
16 patient-provider agreement;

17 46. "Serious illness" means a medical illness or physical
18 injury or condition that substantially affects quality of life for
19 more than a short period of time. "Serious illness" includes, but
20 is not limited to, Alzheimer's disease or related dementias, lung
21 disease, cancer, heart failure, renal failure, liver failure or
22 chronic, unremitting or intractable pain such as neuropathic pain;
23 and
24

1 47. "Surgical procedure" means a procedure that is performed
2 for the purpose of structurally altering the human body by incision
3 or destruction of tissues as part of the practice of medicine. This
4 term includes the diagnostic or therapeutic treatment of conditions
5 or disease processes by use of instruments such as lasers,
6 ultrasound, ionizing, radiation, scalpels, probes or needles that
7 cause localized alteration or transportation of live human tissue by
8 cutting, burning, vaporizing, freezing, suturing, probing or
9 manipulating by closed reduction for major dislocations or
10 fractures, or otherwise altering by any mechanical, thermal, light-
11 based, electromagnetic or chemical means.

12 SECTION 2. This act shall become effective November 1, 2020.

13 Passed the Senate the 9th day of March, 2020.

14

15

Presiding Officer of the Senate

16

17 Passed the House of Representatives the ____ day of _____,

18 2020.

19

20

Presiding Officer of the House
of Representatives

21

22

23

24